Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PODNL1 Methylation Serves as a Prognostic Biomarker and Associates with Immune Cell Infiltration and Immune Checkpoint Blockade Response in Lower-Grade Glioma.

International journal of molecular sciences - 22 Nov 2021

Noor Humaira, Zaman Ashraf, Teo Charles, Sughrue Michael E

Abstract excerpt

Lower-grade glioma (LGG) is a diffuse infiltrative tumor of the central nervous system, which lacks targeted therapy. We investigated the role of Podocan-like 1 (PODNL1) methylation in LGG clinical outcomes using the TCGA-LGG transcriptomics dataset. We identified four PODNL1 CpG sites, cg07425555, cg26969888, cg18547299, and cg24354933, which were associated with unfavorable overall survival (OS) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to CpG Islands

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CTLA-4 Antigen

Share to Glioma

Share to Immune Checkpoint Inhibitors

Share to Lymphocytes, Tumor-Infiltrating

Share to Neoplasm Grading

Share to Sialoglycoproteins

Source

Open in PubMed Open full text

Identifiers

PMID: 34830454
DOI: 10.3390/ijms222212572
PMCID: PMC8625785

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PODNL1 Methylation Serves as a Prognostic Biomarker and Associates with Immune Cell Infiltration and Immune Checkpoint Blockade Response in Lower-Grade Glioma.PMID 34830454Read ↗

DSN1 may predict poor prognosis of lower-grade glioma patients and may be a potential target for immunotherapySemantic proximity Read ↗

PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.Semantic proximity Read ↗

PTPRN Serves as a Prognostic Biomarker and Correlated with Immune Infiltrates in Low Grade GliomaSemantic proximity Read ↗

Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade GliomaSemantic proximity Read ↗

Uncovering N7-Methylguanosine regulator-mediated methylation modification pattern and Landscape of anti-PD-1/L1 Immunotherapy and immune microenvironment infiltration characterization in Lower-Grade GliomaSemantic proximity Read ↗

Characterization of clinical significance of PD-1/PD-Ls expression and methylation in patients with low grade gliomaSemantic proximity Read ↗

Construction of an immune infiltration-associated ceRNA network and prognostic model for low-grade gliomasSemantic proximity Read ↗

Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomasSemantic proximity Read ↗

Characterization of the Clinical Significance of PD-1/PD-Ls Expression and Methylation in Patients With Low-Grade Glioma.Semantic proximity Read ↗

Identification Of Immune Networks Influenced By Mir-200c In IDH1-Mutant Lower-Grade Gliomas Using WGCNASemantic proximity Read ↗

Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics.Semantic proximity Read ↗

Classification of diffuse lower‐grade glioma based on immunological profilingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.